Last reviewed · How we verify
NCT06284395
Two Schemes Response in Multiple Myeloma
trial testing Bortezomib in Response, Acute Phase in 83 participants. Currently enrolling.
20 March 2024
Quick facts
| Lead sponsor | Hospital General de Mexico |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 83 |
| Start date | 20 November 2023 |
| Primary completion | 20 March 2024 |
| Estimated completion | 30 October 2024 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Bortezomib (bortezomib) — full drug profile →
Conditions studied
- Response, Acute Phase — all drugs for Response, Acute Phase →
- Survivorship — all drugs for Survivorship →
Sponsor
Hospital General de Mexico
Who can join
Adults 18 to 90, any sex, with Response, Acute Phase or Survivorship. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06284395
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bortezomib
Trials testing the same drug.
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
- NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
Other Hospital General de Mexico trials
Trials by the same sponsor.
- NCT07258043 — Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia · recruiting
- NCT06589973 — Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients · recruiting
- NCT06648551 — Diagnostic Performance of Controlling Nutritional Status as a Nutritional Screening Tool in Patients With Inflammatory B · recruiting
- NCT05951803 — Effectiveness of a Psychological Intervention on Mental Health and Sleep. · NA · unknown
- NCT04716738 — Visceral Sensitivity in Women With BS and Sexual Dysfunction · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06284395 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital General de Mexico
- Last refreshed: 2 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06284395.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing